

1 *Navigating contradictions: Salmonella Typhimurium chemotactic responses to conflicting effector*  
2 *stimuli*

3

4 Kailie Franco <sup>1</sup>, Zealon Gentry-Lear <sup>2</sup>, Michael Shavlik <sup>3</sup>, Michael J. Harms <sup>2,3</sup>, and Arden Baylink  
5 <sup>1\*</sup>

6

7 <sup>1</sup> Washington State University, Department of Veterinary Microbiology and Pathology, Pullman,  
8 WA 99164

9 <sup>2</sup> University of Oregon, Institute of Molecular Biology, Eugene, OR, 97403

10 <sup>3</sup> University of Oregon, Department of Chemistry & Biochemistry, Eugene, OR, 97403

11 \* Corresponding author: [arden.baylink@wsu.edu](mailto:arden.baylink@wsu.edu) (A. Baylink)

12

13 **Summary**

14 Chemotaxis controls swimming motility and colonization of many intestinal bacteria, but how  
15 enteric pathogens navigate the complex chemical landscape of the gut, which contains  
16 contradictory chemoattractant and chemorepellent stimuli, remains poorly understood. We find  
17 *Salmonella* Typhimurium requires chemotactic sensing of two opposing signals present in the  
18 intestinal lumen—the microbiota metabolite and bacteriostatic chemorepellent indole, and the  
19 nutrient chemoattractant L-Ser—for efficient invasion of colonic tissue. Despite feces being the  
20 major biological source of indole, accumulating to millimolar levels, non-typhoidal *Salmonella*  
21 are strongly attracted to fecal material because chemoattraction to L-Ser and other attractants  
22 override indole chemorepulsion. This behavior is orchestrated through the chemoreceptor Tsr,  
23 which coordinates a spectrum of distinct rearrangements in the bacterial population structure based  
24 on the ratio of L-Ser to indole. Through seeking niches with the highest L-Ser to indole ratio, *S.*  
25 Typhimurium presumably optimizes nutrient access and avoids regions of high-competitor  
26 density.

27

28 **Keywords:**

29 Chemotaxis, *Salmonella*, chemoeffector, chemohalation, serine, indole, chemoreceptor, Tsr,  
30 microbiome, gastrointestinal pathogen

31

## 32 Introduction

33 Many bacteria that colonize the gastrointestinal tracts of humans and other animals employ  
34 chemotaxis to sense chemical effectors in the gut lumen and swim to environments conducive for  
35 growth and colonization<sup>1-5</sup>. Chemotaxis enables motile bacteria to seek nutrients, avoid toxins,  
36 and respond to molecular cues<sup>1,2,4,5</sup>. This process is controlled by chemoreceptor proteins, which  
37 recognize chemical effectors and transduce signals through a phosphorylation cascade to regulate  
38 flagellar rotation and swimming direction, ultimately determining the spatial and temporal patterns  
39 of bacterial colonization (Fig. 1A)<sup>1,2,6,7</sup>. While many effectors have been studied and characterized  
40 in isolation as attractants or repellents<sup>4,7</sup>, natural environments contain mixtures of opposing  
41 signals. In the enteric lumen, bacteria encounter a complex milieu of conflicting effector signals,  
42 and little is known about how they prioritize these signals to direct their movement and  
43 colonization (Fig. 1B). Ultimately, the colonization topography of bacteria within the gut  
44 influences the health of the host through nutrient absorption, developmental regulation, and  
45 resistance to pathogens<sup>8-10</sup>.

46 A chemical effector of major importance for enteric bacterial communities is indole, an  
47 interbacterial signaling molecule that regulates diverse aspects of bacterial physiology and lifestyle  
48<sup>11-13</sup>. Indole is excreted by gut microbiota as a byproduct of tryptophan metabolism and  
49 accumulates to millimolar levels in human feces (Fig. 1A-B)<sup>11,14,15</sup>. Indole is amphipathic and can  
50 transit bacterial membranes to regulate biofilm formation and motility, suppress virulence  
51 programs, and exert bacteriostatic and bactericidal effects at high concentrations<sup>11-13,15-17</sup>. Indole  
52 was one of the earliest identified chemorepellents, and subsequent work has extensively explored  
53 its role in *Escherichia coli* chemotaxis (Table S1)<sup>13,18-22</sup>. The molecular mechanism by which *E.*  
54 *coli* senses indole remains unclear, but is known to involve the chemoreceptor taxis to serine and  
55 repellents (Tsr) (Fig. 1A-B)<sup>18,20,21</sup>. From this body of work, the hypothesis emerged that indole  
56 repels pathogens and restricts their growth as a mechanism of colonization resistance conferred by  
57 the microbiota<sup>11-13,18,23</sup>. However, no prior work has actually tested whether human fecal material,  
58 the major biological source of indole in the gut, which contains a complex mixture of effectors,  
59 induces chemorepulsion or inhibits pathogen growth at physiologically relevant levels.

60 We were interested in further studying the role of Tsr in navigating contradicting effector  
61 stimuli because this chemoreceptor has an interesting dual function: it both senses chemorepellents  
62 and also recognizes the amino acid and nutrient, L-Ser as a chemoattractant (Fig. 1A-B)<sup>1,24-26</sup>.

63 Prior *in vitro* work with purified effectors showed that when both attractants and repellents are  
64 present, Tsr facilitates “intermediate” responses between chemoattraction and chemorepulsion,  
65 suggesting that, in some cases, navigating conflicting chemotactic stimuli is regulated at the single  
66 chemoreceptor level<sup>20,21</sup>. The mechanisms and temporal dynamics of these intermediate  
67 chemotactic behaviors are mostly uncharacterized, but could be relevant in natural settings that  
68 contain conflicting effectors. We recently reported that many enteric pathogens and pathobionts  
69 possess Tsr orthologues, including the genera *Salmonella*, *Citrobacter*, and *Enterobacter*<sup>24</sup>.  
70 Whether these and other bacteria respond to indole as a chemorepellent has remained unclear  
71 because all prior studies of indole taxis focused on *E. coli* (Table S1).

72 *Salmonella* Typhimurium is a frank pathogen that relies on chemotaxis for enteric invasion  
73<sup>27–30</sup>, and differs fundamentally from *E. coli* because it lacks tryptophanase genes and cannot itself  
74 produce indole, which could provide a novel perspective on indole taxis<sup>31,32</sup>. In this study, we  
75 used the pathogen *S. Typhimurium* as a model to: (1) test the hypothesis that the microbiota  
76 secretion product indole is protective against enteric invasion, (2) investigate if pathogens are  
77 repelled by indole-containing fecal material, and (3) examine how the chemoreceptor Tsr regulates  
78 pathogen spatial localization in response to conflicting chemotactic stimuli of the intestinal  
79 environ. Our study is the first to employ live imaging to directly visualize how enteric pathogen  
80 populations dynamically restructure in response to physiological mixtures of attractants and  
81 repellents. We demonstrate that the ability to navigate conflicting effector signals in fact mediates  
82 efficient pathogen invasion, and that chemotaxis responses to natural biological combinations of  
83 effectors and their impacts on infection outcomes, are not easily predicted based on responses to  
84 individual effectors.

85

## 86 **Results & Discussion**



87

### 88 *Opposing chemoeffector stimuli mediate efficient pathogen invasion in swine colonic explants*

89 We sought to determine whether indole in human fecal matter protects against *S.*  
90 Typhimurium infection and whether this involves chemotaxis mediated by the chemoreceptor Tsr.  
91 To address this, we developed a swine colonic explant model that mimics the architecture and size  
92 of adult human colonic tissue<sup>33–37</sup>. The explant tissue was gently cleaned and treated with various  
93 effector solutions: solubilized human feces, purified indole and/or L-Ser at fecal-relevant

94 concentrations, or buffer as a control (see Method Details). The tissue was then exposed to co-  
95 infection with wild-type (WT) *S. Typhimurium* strain IR715 and either a *cheY* mutant (motile but  
96 non-responsive to chemoeffector stimuli) or a *tsr* deletion mutant (Fig. 1C-D, Key Resources  
97 Table)<sup>28</sup>. To assess the role of chemotaxis in infection, we quantified total bacteria harvested from  
98 tissue homogenates and enumerated intracellular bacteria using a gentamicin wash at 1-, 3-, and  
99 6-h post-infection (Fig. 1C, Method Details)<sup>38,39</sup>. For buffer-treated explants, WT *S.*  
100 *Typhimurium* showed a modest time-dependent advantage in colonization and invasion compared  
101 to chemotactic mutants, indicating that chemotaxis, and specifically Tsr, promotes tissue  
102 colonization under baseline conditions (Fig. 1E, Fig. S1A-B).

103 Contrary to the hypothesis that indole-rich fecal matter would inhibit pathogen  
104 colonization, we found that fecal treatment significantly enhances intracellular invasion of WT *S.*  
105 *Typhimurium*, providing a >100-fold competitive advantage mediated by Tsr (Fig. 1F, Fig. S1C-  
106 D). Analysis of the liquified human fecal matter used in this study revealed an indole concentration  
107 of 862  $\mu$ M, consistent with previously reported ranges (0.5–5 mM) (Fig. 1D, Method Details)<sup>11,14-</sup>  
108 <sup>17</sup>. However, when colonic tissue was treated with purified indole at the same concentration, the  
109 competitive advantage of WT over the chemotactic mutants was abolished (Fig. 1G, Fig. S1E-F).  
110 Given that Tsr mediates attraction to L-Ser in both *E. coli* and *S. Typhimurium*, we hypothesized  
111 that L-Ser present in feces might be responsible for increased colonization of fecal-treated tissue  
112 <sup>1,24,40,41</sup>. However, treatment with 338  $\mu$ M L-Ser, the concentration present in our fecal sample  
113 (Fig. 1D, Method Details), actually reduces the competitive advantage of WT bacteria, similar to  
114 the effect of indole alone (Fig. 1H). While treatments with either indole or L-Ser alone reduce the  
115 WT advantage, total bacterial loads are similar, suggesting that neither effector is “protective” in  
116 terms of total infection burden (Fig. S1). We then wondered whether Tsr might require sensing of  
117 both indole and L-Ser in combination to coordinate infection. Interestingly, we found that treatment  
118 containing a mixture of indole and L-Ser restores the competitive advantage of WT (Fig. 1I, Fig.  
119 S1I-J). Thus, we discovered that fecal material, the major biological source of indole in the gut,  
120 does not protect against *S. Typhimurium* invasion, and that the fecal effectors indole and L-Ser, in  
121 combination, direct efficient colonic invasion through chemotaxis and the chemoreceptor Tsr (Fig.  
122 1, Fig. S1).




**Fig. 1.** Tsr and chemotaxis mediate efficient pathogen invasion of colonic tissue in the presence of conflicting chemotactic stimuli. A-B. Overview of the role of Tsr in chemotactic responses and premise of this study. C. Experimental design of colonic explant infections. D. Serine (presumed to be nearly 100% L-Ser, see Materials & Methods) and indole content of liquid human fecal treatments. E-I. Competitive indices (CI) of colony-forming units (CFU) recovered from co-infected swine explant tissue, either from the total homogenate (open box and whiskers plots), or the invaded intracellular population (checkered box and whisker plots), as indicated (n=5). Boxes show median values (line) and upper and lower quartiles, and whiskers show max and min values. Effect size (Cohen's *d*) and statistical significance are noted (not significant, ns; \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$ ). See also Figure S1.

124 *Non-typhoidal S. enterica are attracted to human feces despite high indole content*

125 Having found that Tsr mediates colonic invasion for *S. Typhimurium*, we next sought to learn what  
126 chemotactic behaviors this chemoreceptor orchestrates in response to human fecal material; given  
127 the high concentration of indole, we expected to observe chemorepulsion based on earlier studies  
128 of Tsr function in *E. coli* (Fig. 1D, Table S1) <sup>18-21</sup>. We employed the chemosensory injection rig  
129 assay (CIRA) for live-imaging of bacterial chemotaxis responses to a source of effectors injected  
130 through a glass microcapillary <sup>24</sup>. In this assay, chemoattraction is observed as an influx of cells  
131 toward the effector source and chemorepulsion as decreasing cells (Figure S2). As described  
132 previously, effector injection introduces a steep microgradient, and using mathematical modeling  
133 of the diffusion of the fecal sources of indole and L-Ser, we can approximate the local  
134 concentrations experienced by bacteria at a given distance from the injection source, which for  
135 most of the field of view is in the picomolar to low nanomolar range (Fig. 2A, Method Details) <sup>24</sup>.

136 Over five minutes, we found both WT and *tsr* exhibit strong chemoattraction to fecal  
137 material, whereas *cheY* remains randomly distributed (Fig. 2B, Movie S1). By examining the radial  
138 distribution of the bacterial populations, we found WT more tightly centers around the treatment  
139 source than *tsr* (Fig. 2C-E, Movie S1). In terms of the rate of accumulation of bacteria at the  
140 treatment source, the chemoattraction of *tsr* lags behind the WT for the first 120 s (Fig. 2F-G,  
141 Movie S1). We wondered how these deficiencies in fecal attraction might translate to direct  
142 competition, where different strains are experiencing the same treatment source simultaneously.  
143 To address this, we performed CIRA with solubilized human feces and two strains present in the  
144 same pond, which we tracked independently through fluorescent markers (Fig. 3). As expected,  
145 WT shows a strong chemoattraction response versus *cheY* (Fig. 3A, Movie S2). Interestingly, we  
146 found that when competed directly, WT vastly outperforms *tsr*, with the maximal bacterial  
147 distribution in proximity to the treatment source higher by about 4-fold (Fig. 3B, Movie S2).



**Fig. 2.** *Salmonella Typhimurium* exhibits attraction toward liquid human fecal material. A. Diffusion modeling showing calculated local concentrations in CIRA experiments with liquid human fecal material. B. Max projections of representative *S. Typhimurium* IR715 responses to a central source of liquid human fecal material. C-E. Mean bacterial distribution at 10 s intervals. F-G. Temporal analyses of area under the curve (AUC) or relative number of bacteria within 150  $\mu\text{m}$  of the source. Effect size (Cohen's  $d$ ) comparing responses of WT and *tsr* attraction at 120 s post-treatment is indicated. Data are means and error bars are standard error of the mean (SEM,  $n=3-5$ ). See also Movie S1, Table S1 and Figure S2.

148

149 These data confirm that despite its high indole content, *S. Typhimurium* is attracted to human fecal  
150 material through chemotaxis, and this response involves Tsr, although not as the sole mediator.  
151 We expect the attraction of the *tsr* mutant is explained by the fact that *S. Typhimurium* possesses  
152 other chemoreceptors that detect glucose, galactose, and L-Asp as chemoattractants, which are  
153 present in human feces<sup>1,7,42-45</sup>.

154

To understand the broader relevance of these behaviors to enteric infections, we examined  
155 chemotaxis responses to fecal material among diverse *Salmonella* serovars and strains responsible  
156 for human infections. Using dual-channel imaging, we compared *S. Typhimurium* IR715 with a  
157 clinical isolate of *S. Typhimurium*, SARA1, and found both strains exhibit fecal attraction,  
158 although SARA1 shows a slightly weaker response (Fig. 3C, Movie S3). We then tested a clinical  
159 isolate of *S. Newport*, an emerging cause of salmonellosis in the United States and Europe<sup>46,47</sup>.  
160 This strain is strongly attraction to fecal material, with a tighter accumulation of cells at the

161 treatment source than *S. Typhimurium* IR715 (Fig. 3D, Movie S3). Lastly, we examined a clinical  
162 isolate of *S. Enteritidis*, a zoonotic pathogen commonly transmitted from poultry, which displays  
163 weak attraction to fecal material (Fig. 3E, Movie S3)<sup>47</sup>. Overall, we found that chemoattraction to  
164 fecal material is conserved among non-typhoidal *Salmonella* serovars responsible for human  
165 infections, although the degree of attraction varies. Notably, despite the high indole content in  
166 feces, none of the strains tested exhibit chemorepulsion.

167


### 168 *Mediation of opposing chemotactic responses by Tsr*

169 We wondered if our inability to observe repulsion from fecal material might be due to *S.*  
170 *Typhimurium* not sensing indole as a chemorepellent since this chemotactic response has only  
171 been previously described for *E. coli* (Table S1). We again employed CIRA to address this  
172 question, comparing chemotaxis responses to either 5 mM L-Ser or 5 mM indole, and found that  
173 *S. Typhimurium* responded rapidly to these two effectors as chemoattractants and chemorepellents,  
174 respectively (Fig. S2H-I). Treatment with 5 mM indole, a concentration at the upper end of what  
175 occurs in the human gut<sup>17</sup>, induces rapid chemorepulsion with the bacteria vacating the region  
176 proximal to the source (Fig. S2B). Interestingly, the chemorepulsion response occurs faster than  
177 chemoattraction, with a zone of avoidance clearly visible within the first 10 s of indole exposure  
178 (Fig. S2I, Movie S4).

179 We next wondered if perhaps our fecal treatments contained insufficient indole to elicit  
180 chemorepulsion from *S. Typhimurium*. To identify the effective source concentrations that drive  
181 indole chemorepulsion and understand the temporal dynamics of this response, we performed a  
182 titration of indole across 0.05-10 mM (Fig. 3F). At all concentrations tested, indole induces  
183 chemorepulsion, and the bacteria avoid the treatment source for the duration of the 5-minute  
184 experiment (Fig. 3F-G). At source concentrations exceeding 3 mM, essentially all motile cells  
185 vacate the field of view within 60 s (Fig. 3F-G). Integrating these chemorepulsion responses and  
186 fitting them to a Monod curve suggests an indole source concentration of approximately 67  $\mu$ M is  
187 sufficient for half-maximal ( $K_{1/2}$ ) chemorepulsion (Fig. 3H). These data show that even though we  
188 observed a strong chemoattraction response to fecal material, indole at the concentration present  
189 in fecal material, and far lower, is indeed a strong chemorepellent for *S. Typhimurium*.

190 Based on its function in *E. coli*, we hypothesized that both indole chemorepulsion and L-  
191 Ser chemoattraction for *S. Typhimurium* could be partly or fully mediated through Tsr<sup>7,18,26</sup>.





**Fig. 3.** Fecal indole is insufficient for chemorepulsion but indole in isolation is a strong chemorepellent. A-E. Dual-channel imaging of chemotactic responses to solubilized human feces by WT *S. Typhimurium* IR715 (pink) and isogenic mutants or clinical isolate strains, as indicated. Shown are max projections at time 295-300 s post-treatment. Data are means and error bars are standard error of the mean (SEM, n=3-5). See also Movies S2-S3. F. Representative max projections of responses at 295-300 s of indole treatment. G-H. Quantification of chemorepulsion as a function of indole concentration (n=3-5). I-K. Comparison of WT and *tsr* mutant responses to L-Ser or indole. See also Fig. S2. L-M. Isothermal titration calorimetry (ITC) experiments with 50  $\mu$ M *S. Typhimurium* Tsr ligand-binding domain (LBD) and indole, or with L-Ser in the presence of 500  $\mu$ M indole. Data are means and error bars are standard error of the mean (SEM, n=3-5). AUC indicates area under the curve. Scale bars are 100  $\mu$ m. See also Movies S2-S3.

193 We compared the chemotactic responses of the WT and *tsr* strains when exposed to sources of  
194 these effectors, and found Tsr to be required for both chemorepulsion from indole and  
195 chemoattraction to L-Ser (Fig. 3I-K). The canonical mode of chemoreceptor effector recognition  
196 involves binding of the effector to the ligand-binding domain (LBD) <sup>7,48</sup>, but the mechanism by  
197 which indole is sensed through Tsr has not been elucidated. We recently reported the first crystal  
198 structure of *S. Typhimurium* Tsr LBD, which clearly defines how the binding site recognizes the  
199 L-Ser ligand (PDB code: 8fyv), and we thought it unlikely indole can be accommodated at the  
200 same site <sup>24</sup>. Nevertheless, to test whether the Tsr LBD binds indole directly, we expressed and  
201 purified the LBD, corresponding to the soluble periplasmic portion, and performed isothermal  
202 titration calorimetry (ITC). These data show that no binding occurs between the Tsr LBD and  
203 indole (Fig. 3L). We next wondered if indole acts as an allosteric regulator, possibly through  
204 interacting with the L-Ser bound form or interfering with L-Ser recognition. To address these  
205 possibilities, we performed ITC of 50  $\mu$ M Tsr LBD with L-Ser in the presence of 500  $\mu$ M indole  
206 and observed a robust exothermic binding curve and  $K_D$  of 5  $\mu$ M, identical to the binding of L-Ser  
207 alone (Fig. 3M) <sup>24</sup>. These data indicate that indole does not alter the Tsr LBD affinity for L-Ser.

208 We conclude that Tsr senses indole through an atypical mechanism, which might either  
209 involve regulation through a solute-binding protein <sup>18,49</sup>, responsiveness to perturbation in the  
210 proton motor force <sup>13</sup>, or binding to a different region other than the periplasmic LBD. Our findings  
211 reveal that while indole acts as a chemorepellent for *S. Typhimurium* in isolation, sensed through  
212 Tsr, its presence within fecal material mixed with other effectors is insufficient to elicit  
213 chemorepulsion.

214

215 *Compromising between conflicting effector signals through chemohalation*

216 Earlier work with *E. coli* revealed that exposure to mixtures of L-Ser and indole can generate

217 intermediate chemotactic responses between chemoattraction and chemorepulsion after prolonged  
218 exposure (1-6 h) (Table S1) <sup>20</sup>. Having confirmed that Tsr in *S. Typhimurium* mediates opposing  
219 chemotactic responses to the chemoattractant L-Ser and the chemorepellent indole in isolation, we  
220 next sought to learn how the bacterial population behaves when confronted with physiological  
221 combinations of these effectors. To address this, we performed a series of CIRA experiments with  
222 500  $\mu$ M L-Ser and increasing concentrations of indole at L-Ser:indole molar ratios of 10:1, 1:1, or  
223 1:10 (Fig. 4A-D, Movie S4).

224 These experiments reveal a fascinating transition in the distribution of the pathogen  
225 population as a function of increasing chemorepellent, which occurs within minutes of exposure  
226 (Fig. 4A-D, Movie S4). With only chemoattractant present, the bacterial population organizes  
227 tightly around the effector source (Fig. 4A, Movie S4). When indole is introduced at a  
228 concentration 10-fold lower than L-Ser, the bacterial distribution still exhibits chemoattraction but  
229 becomes more diffuse (Fig. 4B, Movie S4). At a 1:1 ratio of chemoattractant and chemorepellent,  
230 a novel population structure emerges in which the swimming bacteria are attracted toward the  
231 source but form a halo around the treatment with an interior region of avoidance (Fig. 4C, Fig. 4E,  
232 Movie S4). When the concentration of indole is 10-fold higher than L-Ser, the bacteria exhibit a  
233 wider zone of avoidance (Fig. 4D-E, Movie S4). Interestingly, whereas 5 mM indole on its own  
234 induces strong chemorepulsion (Fig. S2I, Movie S4), the addition of 10-fold lower L-Ser  
235 effectively converts the behavior to a null response (Fig. 4D-E, Movie S4). This demonstrates that  
236 even at the highest concentrations of indole *S. Typhimurium* might encounter in the gut, the  
237 presence of chemoattractant can override indole chemorepulsion.

238 The intermediate responses to opposing effector mixtures bear similarities to CIRA  
239 experiments with fecal material, some of which also exhibited a halo-like structure around the  
240 treatment source (Fig. 2, Movies S2-S3). To our knowledge, there exists no consensus term for  
241 intermediate chemotaxis responses of this nature, so here we introduce “chemohalation,” in  
242 reference to the halo formed by the cell population, and which is congruent with the established  
243 nomenclature of chemoattraction and chemorepulsion. We expect chemohalation is a compromise  
244 in positional location at the population level between the chemoattraction driven by L-Ser and the  
245 chemorepulsion driven by indole. Across these experiments, the interior zone of avoidance roughly  
246 corresponds to where the local concentration of indole exceeds 10 nM (Fig. 4E-F). In a biological  
247 setting, we presume that the distribution bias orchestrated by chemohalation regulates the


248 probability that cells will colonize, adhere, and transition to sessility at a given site; the greater the  
249 local indole content, the wider the zone of avoidance and the less likely tissue invasion occurs.

250 We questioned why non-typhoidal *Salmonella* are attracted to a biological solution with  
251 high concentrations of indole, a chemical reported to inhibit bacterial growth<sup>12,50,51</sup>. We examined  
252 how bacterial growth is affected by 0-25 mM indole or L-Ser in a background of minimal media  
253 (MM). As expected, increasing amounts of the nutrient L-Ser provide a growth advantage for all  
254 *Salmonella* strains analyzed, with maximal benefit achieved by approximately 500  $\mu$ M (Fig. 4G).  
255 Equivalent treatments with indole show tolerance up to approximately 1 mM, with growth  
256 inhibition occurring in the 1-5 mM range and lethality occurring at indole concentrations greater  
257 than 5 mM (Fig. 4H). However, adding L-Ser in a background of 500  $\mu$ M indole provides only a  
258 small growth enhancement (Fig. 4I), and addition of 500  $\mu$ M L-Ser increases tolerance for indole  
259 up to about 1 mM, above which indole toxicity is unavoidable (Fig. 4J). So, we conclude that  
260 mixtures of these effectors also impact growth differently than the effectors in isolation, and the  
261 relative attraction to combinations of these effectors relates to their propensity to enhance or inhibit  
262 growth.

263

## 264 **Conclusions**

265 Bacteria in the human gastrointestinal tract encounter complex chemical landscapes that contain  
266 both chemoattractants and chemorepellents. However, chemotaxis responses are often studied in  
267 isolation, outside of their biological and ecological contexts, which can lead to an over- or  
268 underestimation of the roles specific interactions play in natural settings. In the present work, we  
269 contribute to an emerging understanding that bacteria exhibit rapid and well-orchestrated  
270 responses to conflicting stimuli distinct from chemoattraction or chemorepulsion and relate these  
271 chemotactic compromises to enteric infection and pathogen growth (Fig. S3)<sup>20,52</sup>. Previously, no  
272 study had addressed whether bacteria other than *E. coli* sense indole as a chemorepellent. In the  
273 model system we investigated, we confirm that *S. Typhimurium* utilizes the chemoreceptor Tsr to  
274 respond to indole as a chemorepellent and L-Ser as a chemoattractant (Fig. 3). Further, we show  
275 that physiological mixtures of these effectors induce the behavior we define here as chemohalation,  
276 where the bacteria accumulate at a distance from the treatment source and form a halo with an  
277 interior zone of avoidance (Fig. 3, Fig. 4, Fig. S2, Movie S4). Our study is the first to capture real-  
278 time videos of this phenomenon for an enteric pathogen and visualize how the population structure



**Fig. 4.** *S. Typhimurium* mediates distinct chemotactic responses based on the ratio of L-Ser to indole. A-D. Representative max projections of responses to treatments of L-Ser and indole at 295-300 s, as indicated. E. Relative bacterial distribution in response to treatments of 500  $\mu\text{M}$  L-Ser and varying amounts of indole, from panels A-D, with the mean value normalized to 100%. F. Diffusion modeling of local effector concentrations based on sources of 5 mM indole (dark brown), 500  $\mu\text{M}$  L-Ser (blue), 500  $\mu\text{M}$  indole (light brown), and 50  $\mu\text{M}$  indole (yellow) are shown as dashed lines. The approximate local concentration of indole that elicits a transition in chemotactic behavior is highlighted in light blue. Data are means and error bars are standard error of the mean (SEM,  $n=3-5$ ). Scale bars are 100  $\mu\text{m}$ . G-H. Bacterial growth as a function of L-Ser or indole, at the time point where the untreated culture reaches  $A_{600}$  of 0.5. I-J. Bacterial growth +/- pretreatment with 500  $\mu\text{M}$  indole or L-Ser, and increasing concentrations of indole or L-Ser, as indicated at the time point where the untreated culture reaches  $A_{600}$  of 0.5. Data are means and error bars are standard error of the mean (SEM,  $n=8-24$ ). See also Figure S3.

279

280

281 changes based on the ratio of attractant to repellent, ranging from chemoattraction, diffuse  
282 chemoattraction, chemohalation, diffuse chemohalation, and chemorepulsion (Fig. 4, Fig. S2, Fig.  
283 S3, Movie S4). These dynamic micron-scale population structures would be difficult or impossible  
284 to detect and quantify without directly viewing them through live imaging.

285 We predicted that human fecal material, rich in indole, would elicit chemorepulsion, inhibit  
286 pathogen growth, and protect against infection. Instead, we found that chemotactic sensing of  
287 human fecal material promotes colonic invasion, predominantly eliciting chemoattraction or  
288 chemohalation (Fig. 1, Fig. S1, Fig. 2, Movies S1-S3). We also found that chemotactic sensing of  
289 opposing effectors mediates efficient colonic invasion but provides no advantage when only a  
290 single effector is present (Fig. 1, Fig. S1). As evidenced by the phenomenon of chemohalation, the  
291 bacteria bias their spatial location based on the ratio of chemoattractant to chemorepellent, and we  
292 expect this behavior functions to rank colonization niches and regulate the probability of invading  
293 specific sites. In the context of *S. Typhimurium* infection, we propose that Tsr orchestrates a  
294 compromise between seeking niches rich in nutrients, signaled by local L-Ser concentrations, and  
295 avoiding niches with high microbial competition, indicated by local indole concentrations (Fig.  
296 S3). Chemorepulsion from indole can be overridden by the presence of chemoattractants, and *S.*  
297 *Typhimurium* growth is quite tolerant of indole within physiological ranges, suggesting the  
298 bacteria generally prioritize nutrient acquisition over the inhibitory effects of indole (Fig. 4). Since  
299 the enteric lumen may never be devoid of attractant stimuli, it is possible that outright  
300 chemorepulsion from a source of indole may not actually occur *in vivo*.

301 Having characterized and confirmed the dual sensing role of Tsr for *S. Typhimurium*, we  
302 speculate that the diverse bacterial species that possess Tsr orthologues, particularly common  
303 among *Enterobacteriaceae*<sup>24</sup>, are capable of similar chemohalation behaviors and regulating taxis  
304 based on local indole content, further supporting indole as a key regulator of polymicrobial  
305 communities of the gut<sup>12,16</sup>. Recently, we reported on *Enterobacteriaceae* chemotactic sensing of  
306 blood serum, another complex biological effector source at the host-pathogen interface, and those  
307 responses appear to involve chemohalation<sup>24</sup>. Evidence of chemohalation is also seen in the case  
308 of the gastric pathogen *Helicobacter pylori* responding to mixtures of urea, a chemoattractant, and  
309 acid, a chemorepellent<sup>53,54</sup>. Continuing to investigate chemohalation behaviors and understanding  
310 how they coordinate bacterial colonization may provide important insights into how chemotaxis  
311 confers fitness advantages in natural environments.

312 **STAR Methods**

313 RESOURCE AVAILABILITY

314 KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Bacterial Strains</b>		
<i>S. enterica</i> Typhimurium IR715 nalidixic acid derivative of ATCC 14028	Rivera-Chávez, F. et al. <sup>28</sup>	N/A
<i>S. enterica</i> Typhimurium IR715 $\Delta cheY::Tn10$ (Tet <sup>R</sup> )	Rivera-Chávez, F. et al. <sup>28</sup>	N/A
<i>S. enterica</i> Typhimurium IR715 $\Delta tsr::pFR3$ (Cm <sup>R</sup> )	Rivera-Chávez, F. et al. <sup>28</sup>	N/A
<i>S. enterica</i> SARA1	Beltran, P. et al. <sup>55</sup>	N/A
<i>S. enterica</i> Newport	Shariat, N. et al. <sup>46</sup>	M11018046001A
<i>S. enterica</i> Enteriditis	Shariat, N. et al. <sup>46</sup>	05E01375
<i>E. coli</i> BL21-DE3	Millipore-Sigma	Cat# 70954-3
<b>Biological Samples</b>		
Single Human Donor Fecal Sample	Lee BioSolutions	Cat# 991-18
<b>Chemicals, Peptides, and Recombinant Proteins</b>		
L-Serine	Fisher	Cat# 56-45-1
Indole	Sigma	Cat# I3408-100G
Hydroxylamine hydrochloride	Sigma	Cat# 159417-100G
<b>Recombinant DNA</b>		
pXS-sfGFP	Glenn et al. <sup>24</sup>	N/A
pXS-mPlum	Glenn et al. <sup>24</sup>	N/A
pET-30a(+)-SeTsrLBD	Glenn et al. <sup>24</sup>	N/A
<b>Software and Algorithms</b>		
Matlab R2022a	The MathWorks Inc., Natick, Massachusetts, USA	<a href="https://www.mathworks.com">Mathworks.com</a>
Fiji	ImageJ, Bethesda, Maryland, USA <sup>56</sup>	<a href="https://fiji.sc/">Fiji Home</a>
TrackingGUI_rp	R. Parthasarathy <sup>57</sup>	<a href="#">TrackingGUI Public</a>

315

316 *Lead contact*

317 Further information and requests for resources and reagents should be directed to and will be  
 318 fulfilled by the lead contact, Arden Baylink ([arden.baylink@wsu.edu](mailto:arden.baylink@wsu.edu)).

319

320 *Materials availability*

321 Strains and plasmids generated in this study will be made available upon request by the Lead  
 322 Contact with a completed Materials Transfer Agreement.

323

324 *Data availability*

325 Source data from this work are archived and available upon request by the Lead Contact. This  
326 paper does not report original code. Any additional information required to reanalyze the data  
327 reported in this paper is available from the lead contact upon request.

328

329 EXPERIMENTAL MODEL AND STUDY DETAILS

330 All methods were carried out in accordance with relevant guidelines, regulations, and state and  
331 federal law. Experimental protocols were approved by the Institutional Biosafety Committee (IBC)  
332 of Washington State University (#1372).

333

334 *Bacterial strains and growth conditions*

335 Bacterial strains and plasmids used in this study are listed in Table 1. As previously described<sup>24</sup>,  
336 bacteria intended for chemotaxis assays were grown overnight in tryptone broth (TB) with  
337 antibiotic selection, as appropriate. Motile bacteria were prepared with a 1:1000 back-dilution and  
338 grown shaking for approximately 4 hours at 37° C to reach A<sub>600</sub> of 0.5. Cells were centrifuged,  
339 washed, and resuspended in a chemotaxis buffer (CB) containing 10 mM potassium phosphate  
340 (pH 7), 10 mM sodium lactate, and 100 µM EDTA to A<sub>600</sub> of 0.2 and rocked gently at room  
341 temperature until fully motile. For *in vitro* growth analyses, cultures were grown overnight in  
342 Lysogeny Broth (LB) at 37° C. Subsequently, 5 µl of A<sub>600</sub> 2.0 cells were used to inoculate 200 µl  
343 of minimal media (MM), containing 47 mM Na<sub>2</sub>HPO<sub>4</sub>, 22 mM KH<sub>2</sub>PO<sub>4</sub>, 8 mM NaCl, 2mM  
344 MgSO<sub>4</sub>, 0.4% glucose (w/v) 11.35 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 100 µM CaCl<sub>2</sub> and L-Ser and/or indole at the  
345 described concentrations, and cultured in a 96-well microtiter plate. Cultures were grown at 37° C  
346 and monitored by A<sub>600</sub> readings at 5-minute intervals.

347

348 METHOD DETAILS

349

350 *Chemosensory injection rig assay (CIRA)*

351 CIRA was performed as described previously<sup>24</sup>. Briefly, an Eppendorf Femtotip 2 microcapillary  
352 containing the treatment of interest was lowered into a pond of 50 µl of motile cells using a Sutter  
353 micromanipulator. An injection flow of effector into the pond at approximately 300 fl per minute  
354 was achieved using a Femtojet 4i set to P<sub>c</sub> 35. Solubilized fecal treatments were prepared by



355 dissolving 1 g of commercially obtained human feces (Innovative Research) in 10 ml of CB. The  
356 solution was clarified by centrifugation at 10,000 g for 20 minutes, followed by sterile filtration  
357 through a 0.2  $\mu\text{m}$  filter. Treatment solutions of indole and L-Ser were also diluted into CB and  
358 sterile-filtered before application. Videos were recorded using an inverted Nikon Ti2 microscope  
359 with heated sample chamber at 37 °C.

360

### 361 *CIRA microgradient modeling*

362 Modeling the microgradient generated through CIRA was performed as described earlier<sup>24</sup>, based  
363 on the continual injection and diffusion of an effector from a fixed-point source. Briefly, diffusion  
364 is modeled as a 3D process where the diffusing substance is gradually and continuously introduced  
365 at a fixed point within a large surrounding fluid volume. The substance is prepared at a  
366 concentration of  $M_s$  (typically between 0.5  $\mu\text{M}$  and 5 mM) and injected at a volume rate of  $Q =$   
367 305.5 fl/min. The species then diffuses into the ambient fluid with a diffusion constant  $D$ .

$$368 \quad C(r, t) = \frac{q}{4\pi Dr} \operatorname{erfc} \frac{r}{2\sqrt{Dt}}$$

369 Here,  $r$  is the distance from the point source,  $t$  is the time from initial injections,  $q$  is the injection  
370 rate of the species (equal to  $M_s Q$ ), and  $C$  is the species concentration.

371

### 372 *Purification of recombinant S. Typhimurium Tsr LBD*

373 Purification of *S. Typhimurium* Tsr LBD was performed as described previously<sup>24</sup>. Rosetta  
374 BL21(DE3) *E. coli* cells with a Tsr-LBD-pet-30a(+) vector were grown with LB and 20  $\mu\text{g}$   
375 kanamycin and induced at  $A_{600}$  of 0.8 with 0.4 mM isopropyl  $\beta$ -D-1-thiogalactopyranoside (IPTG).  
376 Cells were harvested after 3 h of growth at 37° C. Cells were lysed, the lysate was clarified through  
377 centrifugation, and the soluble fraction was subjected to an ammonium sulfate precipitation, with  
378 Tsr LBD precipitating in the 20-40% fraction. The fractions were pooled, treated with TEV  
379 protease to remove the N-terminal expression sequence, and purified using an anion exchange  
380 column and Akta FPLC. Lastly, the protein was purified by gel filtration using an S200 column  
381 with a final buffer of 50 mM Tris pH 7.5, 1 mM EDTA, and 150 mM NaCl and stored at 7 mg/ml  
382 at -80 C.

383

384

385

386 *Isothermal titration calorimetry ligand binding studies (ITC)*

387 ITC experiments were performed using a Microcal ITC200 instrument (GE Healthcare). Either  
388 500  $\mu\text{M}$  indole or L-Ser was titrated in 2.5  $\mu\text{L}$  injections into a 200  $\mu\text{L}$  sample cell containing 50  
389  $\mu\text{M}$  Tsr LBD. For the indole/L-Ser competition experiment, 500  $\mu\text{M}$  indole was added to both the  
390 titrant and sample cell, thus providing a constant excess background concentration of indole. For  
391 all experimental conditions, blank titrations were also collected in which indole or L-Ser was  
392 titrated into a cell containing buffer alone. All experiments were performed using thoroughly  
393 degassed samples at 25  $^{\circ}\text{C}$  in 50 mM Tris, 150 mM NaCl, 1 mM EDTA, pH 7.5. The reference  
394 power was set to 5  $\mu\text{cal}/\text{sec}$ . The resulting power curves were integrated using the Origin analysis  
395 software included with the instrument. The heat of dilution was subtracted from each point using  
396 the blank. A single-site binding model was then fit to the data, floating parameters describing the  
397 binding enthalpy ( $\Delta\text{H}$ ), equilibrium constant ( $K_{\text{D}}$ ), and apparent binding stoichiometry ( $n$ ). The  
398 instrument software was used for this purpose.

399

400 *Quantification of indole and serine in human fecal samples*

401 Solubilized human feces was prepared as described above for CIRA and analyzed by mass  
402 spectrometry to determine the molar serine content as a service through the University of  
403 Washington Mass Spectrometry Center. This measurement reflects total serine, of which close to  
404 100% is expected to be L-Ser<sup>24</sup>. As described in earlier work, the indole content of solubilized  
405 human fecal samples was determined using a hydroxylamine-based calorimetric assay with  
406 purified indole as a reference and standard<sup>58</sup>.

407

408 *Explant infection assays*

409 Swine intestinal tissue was acquired from the descending colon of an 8-week-old animal, pursuant  
410 to animal protocol ASAF #7128, approved through the Washington State University IACUC.  
411 Before infection, the luminal side of an approximately 20 by 20 mm piece of swine intestinal  
412 explant tissue was gently washed with PBS to remove fecal matter. Next, the tissue section was  
413 bathed in 2 ml of chemoeffector solution (solubilized human fecal matter, a mixture of 338  $\mu\text{M}$  L-  
414 Ser and 862  $\mu\text{M}$  indole, 338  $\mu\text{M}$  L-Ser alone, or 862  $\mu\text{M}$  indole alone) in a 6-well tissue culture  
415 plate (Celltreat) and incubated at 4 $^{\circ}\text{C}$  for 1 h. Then, tissue was transferred to a 35 mm Mattek dish  
416 where the luminal side of the tissue was exposed to a bacterial solution containing a 1:1 mixture

417 ( $10^9$  CFU each) of WT *S. Typhimurium* IR715 and either the isogenic *tsr* or *cheY* mutant,  
418 suspended in CB at a volume of 300  $\mu$ l. The tissue was then incubated in the dish with the  
419 competing bacteria at 37 °C and 5% CO<sub>2</sub> for 1-, 3-, or 6-h. After, half of the tissue was transferred  
420 into screwcap tubes containing 500  $\mu$ l LB media and 5-10 2.3 mm zirconia beads (BioSpec  
421 Products) on ice and homogenized using a Bead Mill 24 (Fisher Scientific, 6.5 m/s for 60 s, four  
422 times). To enumerate the intracellular bacteria, the other half of the tissue was washed in PBS and  
423 incubated in PBS containing 100 g/ml gentamicin for 1 h at 37 °C and 5% CO<sub>2</sub>, then washed twice  
424 in PBS, as done previously<sup>39,59,60</sup>. The homogenization process was then repeated for the  
425 gentamicin-treated tissue. CFUs were enumerated by 100  $\mu$ l spot plating of 10-fold dilutions on  
426 LB agar plates containing the appropriate antibiotic<sup>39,61</sup>. Competitive index values were calculated  
427 by dividing the number of mutant CFUs by the number of WT CFUs for each treatment and time  
428 point<sup>62,63</sup>.

429

## 430 QUANTIFICATION AND STATISTICAL ANALYSIS

### 431 *Quantification of CIRA data*

432 Videos of chemotactic responses were quantified as described previously<sup>24</sup>. The number of cells  
433 in each frame was calculated by determining a fluorescence intensity ratio per cell for frames pre-  
434 treatment and extrapolated using the ‘plot profile’ function of ImageJ. The distribution of the  
435 bacteria was calculated using the Radial Profile ImageJ plugin. Local background subtraction was  
436 performed based on experiments with the non-chemotactic *cheY* strain to control for  
437 autofluorescence in solubilized fecal samples.

438

### 439 *Statistical Analyses*

440 Competitive indices (CIs) for explant experiments were calculated for each treatment group at  
441 each time point. Log-transformed CI values were obtained by taking the logarithm ( $\log_{10}$ ) of the  
442 original CI measurements. These log-transformed values were then subjected to statistical analysis.  
443 First, a one-sample t-test was performed to determine whether the mean of the log-transformed  
444 CIs significantly differed from zero. In cases where the assumption of normality was violated, the  
445 non-parametric Wilcoxon rank sum test was applied as an alternative. Effect size was assessed  
446 using Cohen’s *d* and calculated using the same log-transformed CIs.

447

448 The formula for Cohen's  $d$  value is as follows:

449

$$450 \quad d = \frac{M_1 - M_2}{\sigma_{\text{pooled}}}$$

451 Where  $M_1$  serves as the mean of the treatment group,  $M_2$  serves as the mean of the control group,  
452 and  $\sigma_{\text{pooled}}$  is the pooled standard deviation:

453

$$454 \quad \sigma_{\text{pooled}} = \sqrt{\frac{\sigma_1^2 + \sigma_2^2}{2}}$$

455 Here,  $\sigma_1$  is the standard deviation of the treatment group, and  $\sigma_2$  is the standard deviation of the  
456 control group.

457

#### 458 **Acknowledgments**

459 Funding for this research was provided by NIAID through awards 1K99AI148587 and  
460 4R00AI148587-03, and funding from Washington State University to AB. Bacterial strains were  
461 provided by Nikki Shariat (University of Georgia, Athens), Nkuchia Mikanatha and Pennsylvania  
462 NARMS and GenomeTrakr Programs, and Andreas Bäumlér (University of California, Davis).  
463 All research on human samples was performed in accordance with, and approval of, the  
464 Institutional Biosafety Committee and Institutional Animal Care and Use Committee at  
465 Washington State University.

466

#### 467 **Author Contributions**

468 K.F. performed the microgradient modeling and explant experiments. A.B. conducted the CIRA  
469 experiments and purification of Tsr-LBD. Z.G. performed bacterial growth experiments. M.S. and  
470 M.J.H. performed the ITC experiments. All authors contributed to data analyses and writing of the  
471 manuscript.

472

#### 473 **Declaration of Interests**

474 A.B. owns Amethyst Antimicrobials, LLC.

475

476

477 **Declaration of generative AI and AI-assisted technologies in the writing process**

478 During the preparation of this work the authors used ChatGPT in order to proof-read and enhance  
479 the clarity and organization of the text. After using this tool/service, the authors reviewed and  
480 edited the content as needed and take full responsibility for the content of the published article.

481

482 **Supplemental Information**

483 Document S1. Table S1 and Figures S1–S3.

484

485 **Movie S1.** Chemotactic response of *S. Typhimurium* IR715 to solubilized human feces, related to  
486 Figure 2. Representative CIRA experiments showing *S. Typhimurium* IR715 WT and mutant  
487 strains responding to a source over 300 s (shown at 10x speed) Viewable at:  
488 <https://www.youtube.com/watch?v=BqUcRN3YwjU>

489

490 **Movie S2.** Chemotactic response of *S. Typhimurium* IR715 WT and chemotactic mutant strains  
491 to solubilized human feces, related to Figure 3. Representative CIRA experiments showing  
492 competition between *S. Typhimurium* IR715 (mPlum) and *cheY*, or *tsr*, as indicated (GFP), over  
493 300 s. Viewable at: <https://www.youtube.com/watch?v=D5JL46b4lsI>

494

495 **Movie S3.** Chemotactic response of *S. enterica* clinical isolates to solubilized human feces, related  
496 to Figure 3. Representative CIRA experiments showing competition between *S. Typhimurium*  
497 IR715 (mPlum) and clinical isolates, as indicated (GFP), responding to a source of solubilized  
498 human feces over 300 s. Viewable at: <https://www.youtube.com/watch?v=dLsFDV0XgpY>

499

500 **Movie S4.** Chemotactic response of *S. Typhimurium* IR715 to L-Ser and indole treatments, related  
501 to Figure 4 and Figure S2. Representative CIRA experiments with treatment sources as indicated,  
502 over 300 s. Viewable at: <https://www.youtube.com/watch?v=bNQMQf2QMek>

503

504 **References**

- 505 1. Zhou, B., Szymanski, C.M., and Baylink, A. (2023). Bacterial chemotaxis in human diseases.  
506 *Trends in Microbiology* 31, 453–467. <https://doi.org/10.1016/j.tim.2022.10.007>.
- 507 2. Keestra, J.M., Carrara, F., and Stocker, R. (2022). The ecological roles of bacterial  
508 chemotaxis. *Nature Reviews Microbiology*. <https://doi.org/10.1038/s41579-022-00709-w>.

- 509 3. Bi, S., and Sourjik, V. (2018). Stimulus sensing and signal processing in bacterial  
510 chemotaxis. *Current Opinion in Microbiology* 45, 22–29.  
511 <https://doi.org/10.1016/j.mib.2018.02.002>.
- 512 4. Matilla, M.A., and Krell, T. (2018). The effect of bacterial chemotaxis on host infection and  
513 pathogenicity. *FEMS Microbiology Reviews* 42. <https://doi.org/10.1093/femsre/fux052>.
- 514 5. Matilla, M.A., Gavira, J.A., and Krell, T. (2023). Accessing nutrients as the primary benefit  
515 arising from chemotaxis. *Current Opinion in Microbiology* 75, 102358.  
516 <https://doi.org/10.1016/j.mib.2023.102358>.
- 517 6. Matilla, M.A., and Krell, T. (2017). Chemoreceptor-based signal sensing. *Current Opinion in*  
518 *Biotechnology* 45, 8–14. <https://doi.org/10.1016/j.copbio.2016.11.021>.
- 519 7. Ortega, Á., Zhulin, I.B., and Krell, T. (2017). Sensory Repertoire of Bacterial  
520 Chemoreceptors. *Microbiol Mol Biol Rev* 81, e00033-17.  
521 <https://doi.org/10.1128/MMBR.00033-17>.
- 522 8. Rogers, A.W.L., Tsolis, R.M., and Bäumlér, A.J. (2020). Salmonella versus the Microbiome.  
523 *Microbiology and Molecular Biology Reviews* 85, e00027-19.  
524 <https://doi.org/10.1128/MMBR.00027-19>.
- 525 9. Vos, W.M. de, Tilg, H., Hul, M.V., and Cani, P.D. (2022). Gut microbiome and health:  
526 mechanistic insights. *Gut* 71, 1020–1032. <https://doi.org/10.1136/gutjnl-2021-326789>.
- 527 10. Hill, J.H., Massaquoi, M.S., Sweeney, E.G., Wall, E.S., Jahl, P., Bell, R., Kallio, K., Derrick,  
528 D., Murtaugh, L.C., Parthasarathy, R., et al. (2022). BefA, a microbiota-secreted membrane  
529 disrupter, disseminates to the pancreas and increases  $\beta$  cell mass. *Cell Metabolism* 34, 1779-  
530 1791.e9. <https://doi.org/10.1016/j.cmet.2022.09.001>.
- 531 11. Li, X., Zhang, B., Hu, Y., and Zhao, Y. (2021). New Insights Into Gut-Bacteria-Derived  
532 Indole and Its Derivatives in Intestinal and Liver Diseases. *Front. Pharmacol.* 12, 769501.  
533 <https://doi.org/10.3389/fphar.2021.769501>.
- 534 12. Lee, J.-H., and Lee, J. (2010). Indole as an intercellular signal in microbial communities.  
535 *FEMS Microbiol Rev* 34, 426–444. <https://doi.org/10.1111/j.1574-6976.2009.00204.x>.
- 536 13. Gupta, R., Rhee, K.Y., Beagle, S.D., Chawla, R., Perdomo, N., Lockless, S.W., and Lele,  
537 P.P. (2022). Indole modulates cooperative protein–protein interactions in the flagellar motor.  
538 *PNAS Nexus* 1, pgac035. <https://doi.org/10.1093/pnasnexus/pgac035>.
- 539 14. Darkoh, C., Chappell, C., Gonzales, C., and Okhuysen, P. (2015). A Rapid and Specific  
540 Method for the Detection of Indole in Complex Biological Samples. *Appl Environ Microbiol*  
541 81, 8093–8097. <https://doi.org/10.1128/AEM.02787-15>.
- 542 15. Chappell, C.L., Darkoh, C., Shimmin, L., Farhana, N., Kim, D.-K., Okhuysen, P.C., and  
543 Hixson, J. (2016). Fecal Indole as a Biomarker of Susceptibility to *Cryptosporidium*  
544 Infection. *Infect Immun* 84, 2299–2306. <https://doi.org/10.1128/IAI.00336-16>.

- 545 16. Ye, X., Li, H., Anjum, K., Zhong, X., Miao, S., Zheng, G., Liu, W., and Li, L. (2022). Dual  
546 Role of Indoles Derived From Intestinal Microbiota on Human Health. *Front. Immunol.* *13*,  
547 903526. <https://doi.org/10.3389/fimmu.2022.903526>.
- 548 17. Kumar, A., and Sperandio, V. (2019). Indole Signaling at the Host-Microbiota-Pathogen  
549 Interface. *mBio* *10*, e01031-19. <https://doi.org/10.1128/mBio.01031-19>.
- 550 18. Yang, J., Chawla, R., Rhee, K.Y., Gupta, R., Manson, M.D., Jayaraman, A., and Lele, P.P.  
551 (2020). Biphasic chemotaxis of *Escherichia coli* to the microbiota metabolite indole. *Proc.*  
552 *Natl. Acad. Sci. U.S.A.* *117*, 6114–6120. <https://doi.org/10.1073/pnas.1916974117>.
- 553 19. Bansal, T., Englert, D., Lee, J., Hegde, M., Wood, T.K., and Jayaraman, A. (2007).  
554 Differential Effects of Epinephrine, Norepinephrine, and Indole on *Escherichia coli*  
555 O157:H7 Chemotaxis, Colonization, and Gene Expression. *Infect Immun* *75*, 4597–4607.  
556 <https://doi.org/10.1128/IAI.00630-07>.
- 557 20. Livne, N., and Vaknin, A. (2022). Collective responses of bacteria to a local source of  
558 conflicting effectors. *Sci Rep* *12*, 4928. <https://doi.org/10.1038/s41598-022-08762-4>.
- 559 21. Englert, D.L., Manson, M.D., and Jayaraman, A. (2009). Flow-Based Microfluidic Device  
560 for Quantifying Bacterial Chemotaxis in Stable, Competing Gradients. *Appl Environ*  
561 *Microbiol* *75*, 4557–4564. <https://doi.org/10.1128/AEM.02952-08>.
- 562 22. Adler, J., and Tso, W.-W. (1974). “Decision”-Making in Bacteria: Chemotactic Response of  
563 *Escherichia coli* to Conflicting Stimuli. *Science* *184*, 1292–1294.  
564 <https://doi.org/10.1126/science.184.4143.1292>.
- 565 23. Kohli, N., Crisp, Z., Riordan, R., Li, M., Alaniz, R.C., and Jayaraman, A. (2018). The  
566 microbiota metabolite indole inhibits *Salmonella* virulence: Involvement of the PhoPQ two-  
567 component system. *PLOS ONE* *13*, e0190613. <https://doi.org/10.1371/journal.pone.0190613>.
- 568 24. Glenn, S.J., Gentry-Lear, Z., Shavlik, M., Harms, M.J., Asaki, T.J., and Baylink, A. (2024).  
569 Bacterial vampirism mediated through taxis to serum. *eLife* *12*, RP93178.  
570 <https://doi.org/10.7554/eLife.93178.3>.
- 571 25. Piñas, G.E., DeSantis, M.D., Cassidy, C.K., and Parkinson, J.S. (2022). Hexameric rings of  
572 the scaffolding protein CheW enhance response sensitivity and cooperativity in *Escherichia*  
573 *coli* chemoreceptor arrays. *Science Signaling* *15*, eabj1737.  
574 <https://doi.org/10.1126/scisignal.abj1737>.
- 575 26. Burt, A., Cassidy, C.K., Ames, P., Bacia-Verloop, M., Baulard, M., Huard, K., Luthey-  
576 Schulten, Z., Desfosses, A., Stansfeld, P.J., Margolin, W., et al. (2020). Complete structure  
577 of the chemosensory array core signalling unit in an *E. coli* minicell strain. *Nat Commun* *11*,  
578 743. <https://doi.org/10.1038/s41467-020-14350-9>.
- 579 27. Winter, S.E., Lopez, C.A., and Bäumlner, A.J. (2013). The dynamics of gut-associated  
580 microbial communities during inflammation. *EMBO Reports* *14*, 319–327.  
581 <https://doi.org/10.1038/embor.2013.27>.

- 582 28. Rivera-Chávez, F., Winter, S.E., Lopez, C.A., Xavier, M.N., Winter, M.G., Nuccio, S.-P.,  
583 Russell, J.M., Laughlin, R.C., Lawhon, S.D., Sterzenbach, T., et al. (2013). Salmonella Uses  
584 Energy Taxis to Benefit from Intestinal Inflammation. *PLoS Pathog* 9, e1003267.  
585 <https://doi.org/10.1371/journal.ppat.1003267>.
- 586 29. Winter, S.E., Thiennimitr, P., Winter, M.G., Butler, B.P., Huseby, D.L., Crawford, R.W.,  
587 Russell, J.M., Bevins, C.L., Adams, L.G., Tsolis, R.M., et al. (2010). Gut inflammation  
588 provides a respiratory electron acceptor for Salmonella. *Nature* 467, 426–429.  
589 <https://doi.org/10.1038/nature09415>.
- 590 30. Cooper, K.G., Chong, A., Kari, L., Jeffrey, B., Starr, T., Martens, C., McClurg, M., Posada,  
591 V.R., Laughlin, R.C., Whitfield-Cargile, C., et al. (2021). Regulatory protein Hild stimulates  
592 Salmonella Typhimurium invasiveness by promoting smooth swimming via the methyl-  
593 accepting chemotaxis protein McpC. *Nat Commun* 12, 348. [https://doi.org/10.1038/s41467-](https://doi.org/10.1038/s41467-020-20558-6)  
594 [020-20558-6](https://doi.org/10.1038/s41467-020-20558-6).
- 595 31. Vega, N.M., Allison, K.R., Samuels, A.N., Klempner, M.S., and Collins, J.J. (2013).  
596 *Salmonella typhimurium* intercepts *Escherichia coli* signaling to enhance antibiotic  
597 tolerance. *Proc. Natl. Acad. Sci. U.S.A.* 110, 14420–14425.  
598 <https://doi.org/10.1073/pnas.1308085110>.
- 599 32. Roager, H.M., and Licht, T.R. (2018). Microbial tryptophan catabolites in health and disease.  
600 *Nat Commun* 9, 3294. <https://doi.org/10.1038/s41467-018-05470-4>.
- 601 33. Kronsteiner, B., Bassaganya-Riera, J., Philipson, C., Viladomiu, M., Carbo, A., Pedragosa,  
602 M., Vento, S., and Hontecillas, R. (2013). Helicobacter pylori Infection in a Pig Model Is  
603 Dominated by Th1 and Cytotoxic CD8<sup>+</sup> T Cell Responses. *Infect Immun* 81, 3803–3813.  
604 <https://doi.org/10.1128/IAI.00660-13>.
- 605 34. Smith, A.C., and Swindle, M.M. (2006). Preparation of Swine for the Laboratory. *ILAR*  
606 *Journal* 47, 358–363. <https://doi.org/10.1093/ilar.47.4.358>.
- 607 35. Poutahidis, T., Tsangaris, T., Kanakoudis, G., Vlemmas, I., Iliadis, N., and Sofianou, D.  
608 (2001). *Helicobacter pylori* -induced Gastritis in Experimentally Infected Conventional  
609 Piglets. *Vet Pathol* 38, 667–678. <https://doi.org/10.1354/vp.38-6-667>.
- 610 36. Boyen, F., Pasmans, F., Van Immerseel, F., Donné, E., Morgan, E., Ducatelle, R., and  
611 Haesebrouck, F. (2009). Porcine *in vitro* and *in vivo* models to assess the virulence of  
612 *Salmonella enterica* serovar Typhimurium for pigs. *Lab Anim* 43, 46–52.  
613 <https://doi.org/10.1258/la.2007.007084>.
- 614 37. Boyen, F., Haesebrouck, F., Vanparys, A., Volf, J., Mahu, M., Van Immerseel, F., Rychlik,  
615 I., Dewulf, J., Ducatelle, R., and Pasmans, F. (2008). Coated fatty acids alter virulence  
616 properties of Salmonella Typhimurium and decrease intestinal colonization of pigs.  
617 *Veterinary Microbiology* 132, 319–327. <https://doi.org/10.1016/j.vetmic.2008.05.008>.



- 618 38. MacBeth, K.J., and Lee, C.A. (1993). Prolonged inhibition of bacterial protein synthesis  
619 abolishes *Salmonella* invasion. *Infect Immun* *61*, 1544–1546.  
620 <https://doi.org/10.1128/iai.61.4.1544-1546.1993>.
- 621 39. Sharma, A., and Puhar, A. (2019). Gentamicin Protection Assay to Determine the Number of  
622 Intracellular Bacteria during Infection of Human TC7 Intestinal Epithelial Cells by *Shigella*  
623 *flexneri*. *BIO-PROTOCOL* *9*. <https://doi.org/10.21769/BioProtoc.3292>.
- 624 40. Kitamoto, S., Alteri, C.J., Rodrigues, M., Nagao-Kitamoto, H., Sugihara, K., Himpl, S.D.,  
625 Bazzi, M., Miyoshi, M., Nishioka, T., Hayashi, A., et al. (2020). Dietary l-serine confers a  
626 competitive fitness advantage to Enterobacteriaceae in the inflamed gut. *Nature*  
627 *Microbiology* *5*, 116–125. <https://doi.org/10.1038/s41564-019-0591-6>.
- 628 41. Sugihara, K., and Kamada, N. (2020). THE ROLE OF DIETARY L-SERINE IN THE  
629 REGULATION OF INTESTINAL MUCUS BARRIER DURING INFLAMMATION.  
630 *Inflammatory Bowel Diseases* *26*, S42–S42. <https://doi.org/10.1093/ibd/zaa010.110>.
- 631 42. Ranque, C.L., Stroble, C., Amicucci, M.J., Tu, D., Diana, A., Rahmannia, S., Suryanto, A.H.,  
632 Gibson, R.S., Sheng, Y., Tena, J., et al. (2020). Examination of Carbohydrate Products in  
633 Feces Reveals Potential Biomarkers Distinguishing Exclusive and Nonexclusive  
634 Breastfeeding Practices in Infants. *J Nutr* *150*, 1051–1057.  
635 <https://doi.org/10.1093/jn/nxaa028>.
- 636 43. Ke, Z., Lu, Z., Li, Q., and Tong, W. (2024). Intestinal glucose excretion: A potential  
637 mechanism for glycemic control. *Metabolism* *152*, 155743.  
638 <https://doi.org/10.1016/j.metabol.2023.155743>.
- 639 44. Larke, J.A., Bacalzo, N., Castillo, J.J., Couture, G., Chen, Y., Xue, Z., Alkan, Z., Kable,  
640 M.E., Lebrilla, C.B., Stephensen, C.B., et al. (2023). Dietary Intake of Monosaccharides  
641 from Foods is Associated with Characteristics of the Gut Microbiota and Gastrointestinal  
642 Inflammation in Healthy US Adults. *The Journal of Nutrition* *153*, 106–119.  
643 <https://doi.org/10.1016/j.tjnut.2022.12.008>.
- 644 45. Shen, X., Jain, A., Aladelokun, O., Yan, H., Gilbride, A., Ferrucci, L.M., Lu, L., Khan, S.A.,  
645 and Johnson, C.H. (2022). Asparagine, colorectal cancer, and the role of sex, genes,  
646 microbes, and diet: A narrative review. *Front Mol Biosci* *9*, 958666.  
647 <https://doi.org/10.3389/fmolb.2022.958666>.
- 648 46. Shariat, N., Kirchner, M.K., Sandt, C.H., Trees, E., Barrangou, R., and Dudley, E.G. (2013).  
649 Subtyping of *Salmonella enterica* Serovar Newport Outbreak Isolates by CRISPR-MVLST  
650 and Determination of the Relationship between CRISPR-MVLST and PFGE Results. *J Clin*  
651 *Microbiol* *51*, 2328–2336. <https://doi.org/10.1128/JCM.00608-13>.
- 652 47. Ferrari, R.G., Rosario, D.K.A., Cunha-Neto, A., Mano, S.B., Figueiredo, E.E.S., and Conte-  
653 Junior, C.A. (2019). Worldwide Epidemiology of *Salmonella* Serovars in Animal-Based  
654 Foods: a Meta-analysis. *Appl Environ Microbiol* *85*, e00591-19.  
655 <https://doi.org/10.1128/AEM.00591-19>.

- 656 48. Gavira, J.A., Gumerov, V.M., Rico-Jiménez, M., Petukh, M., Upadhyay, A.A., Ortega, A.,  
657 Matilla, M.A., Zhulin, I.B., and Krell, T. (2020). How Bacterial Chemoreceptors Evolve  
658 Novel Ligand Specificities. *mBio* *11*, e03066-19. <https://doi.org/10.1128/mBio.03066-19>.
- 659 49. Matilla, M.A., Ortega, A., and Krell, T. (2021). The role of solute binding proteins in signal  
660 transduction. *Computational and Structural Biotechnology Journal* *19*, 1786–1805.  
661 <https://doi.org/10.1016/j.csbj.2021.03.029>.
- 662 50. Chimere, C., Field, C.M., Piñero-Fernandez, S., Keyser, U.F., and Summers, D.K. (2012).  
663 Indole prevents *Escherichia coli* cell division by modulating membrane potential. *Biochim*  
664 *Biophys Acta* *1818*, 1590–1594. <https://doi.org/10.1016/j.bbamem.2012.02.022>.
- 665 51. Melander, R.J., Minvielle, M.J., and Melander, C. (2014). Controlling bacterial behavior  
666 with indole-containing natural products and derivatives. *Tetrahedron* *70*, 6363–6372.  
667 <https://doi.org/10.1016/j.tet.2014.05.089>.
- 668 52. Moore, J.P., Kamino, K., Kottou, R., Shimizu, T.S., and Emonet, T. (2024). Signal  
669 integration and adaptive sensory diversity tuning in *Escherichia coli* chemotaxis. *Cell*  
670 *Systems* *15*, 628-638.e8. <https://doi.org/10.1016/j.cels.2024.06.003>.
- 671 53. Huang, J.Y., Sweeney, E.G., Sigal, M., Zhang, H.C., Remington, S.J., Cantrell, M.A., Kuo,  
672 C.J., Guillemin, K., and Amieva, M.R. (2015). Chemodetection and Destruction of Host  
673 Urea Allows *Helicobacter pylori* to Locate the Epithelium. *Cell Host & Microbe* *18*, 147–  
674 156. <https://doi.org/10.1016/j.chom.2015.07.002>.
- 675 54. Huang, J.Y., Sweeney, E.G., Guillemin, K., and Amieva, M.R. (2017). Multiple Acid  
676 Sensors Control *Helicobacter pylori* Colonization of the Stomach. *PLOS Pathogens* *13*,  
677 e1006118. <https://doi.org/10.1371/journal.ppat.1006118>.
- 678 55. Beltran, P., Plock, S.A., Smith, N.H., Whittam, T.S., Old, D.C., and Selander, R.K. (1991).  
679 Reference collection of strains of the *Salmonella typhimurium* complex from natural  
680 populations. *Journal of General Microbiology* *137*, 601–606.  
681 <https://doi.org/10.1099/00221287-137-3-601>.
- 682 56. Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T.,  
683 Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012). Fiji: an open-source  
684 platform for biological-image analysis. *Nat Methods* *9*, 676–682.  
685 <https://doi.org/10.1038/nmeth.2019>.
- 686 57. Parthasarathy, R. (2012). Rapid, accurate particle tracking by calculation of radial symmetry  
687 centers. *Nat Methods* *9*, 724–726. <https://doi.org/10.1038/nmeth.2071>.
- 688 58. Sugihara, K., Kitamoto, S., Saraithong, P., Nagao-Kitamoto, H., Hoostal, M., McCarthy, C.,  
689 Rosevelt, A., Muraleedharan, C.K., Gilliland, M.G., Imai, J., et al. (2022). Mucolytic  
690 bacteria license pathobionts to acquire host-derived nutrients during dietary nutrient  
691 restriction. *Cell Reports* *40*, 111093. <https://doi.org/10.1016/j.celrep.2022.111093>.

- 692 59. Chandra, K. (2022). Gentamicin Protection assay (Intracellular Survival Assay) for  
693 Salmonella Typhimurium/Typhi v1. Preprint,  
694 <https://doi.org/10.17504/protocols.io.b4zmqx46>  
695 <https://doi.org/10.17504/protocols.io.b4zmqx46>.
- 696 60. Rivera Calo, J., Rubinelli, P.M., and Ricke, S.C. (2024). Gentamicin Susceptibility and  
697 Comparison of Adhesion and Invasion of Caco-2 and HD11 Cell Lines by Salmonella  
698 enterica Serotypes. *Applied Sciences* 14, 3305. <https://doi.org/10.3390/app14083305>.
- 699 61. Ben-David, A., and Davidson, C.E. (2014). Estimation method for serial dilution  
700 experiments. *Journal of Microbiological Methods* 107, 214–221.  
701 <https://doi.org/10.1016/j.mimet.2014.08.023>.
- 702 62. Macho, A.P., Zumaquero, A., Ortiz-Martín, I., and Beuzón, C.R. (2007). Competitive index  
703 in mixed infections: a sensitive and accurate assay for the genetic analysis of *Pseudomonas*  
704 *syringae* –plant interactions. *Molecular Plant Pathology* 8, 437–450.  
705 <https://doi.org/10.1111/j.1364-3703.2007.00404.x>.
- 706 63. Auerbuch, V., Lenz, L.L., and Portnoy, D.A. (2001). Development of a competitive index  
707 assay to evaluate the virulence of *Listeria monocytogenes actA* mutants during primary and  
708 secondary infection of mice. *Infect Immun* 69, 5953–5957.  
709 <https://doi.org/10.1128/IAI.69.9.5953-5957.2001>.

710